<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536769</url>
  </required_header>
  <id_info>
    <org_study_id>86/2011</org_study_id>
    <nct_id>NCT01536769</nct_id>
  </id_info>
  <brief_title>Intestinal and Nasal Microbiota of Patients With Idiopathic Parkinson's Disease</brief_title>
  <official_title>Intestinal and Nasal Microbiota of Patients With Idiopathic Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jorvi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hyvinkää Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peijas Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cause of Parkinson's disease (PD) is unknown and a reliable biomarker to identify PD&#xD;
      patients as early as possible is urgently needed. Nerve cells near the nose and in the gut&#xD;
      become first affected in PD and patients frequently suffer from loss of smell and&#xD;
      constipation. The nose and gut harbor very high amounts of bacteria that influence our body&#xD;
      functions in many ways, even in the brain. The investigators are examining a possible role of&#xD;
      bacteria of the nose and gut in the pathogenesis of PD. This may lead to a better&#xD;
      understanding of what PD causes and may open new possibilities for diagnosis and treatment.&#xD;
&#xD;
      The investigators will recruit 100 PD patients and 100 control subjects. The investigators&#xD;
      will characterize all subjects carefully with respect to clinical symptoms. The investigators&#xD;
      will collect bacterial samples from the nose, mouth and stool of these subjects. Using modern&#xD;
      genomic techniques the investigators will read out the genetic code of all bacteria contained&#xD;
      in these samples and will be able to identify which species of bacteria are present in the&#xD;
      samples. Using complex cluster computing the investigators will compare the pattern of&#xD;
      bacterial species between PD patients and controls and look for specific abnormalities in PD&#xD;
      patients.&#xD;
&#xD;
      If the investigators can detect specific differences of bacterial communities between PD&#xD;
      patients and controls this may point to a role of bacteria as a cause of PD. Since there are&#xD;
      many ways to influence bacterial communities pharmacologically (antibiotics, probiotics) it&#xD;
      will be possible to investigate whether these therapies could alleviate or even reverse PD&#xD;
      symptoms. Furthermore, the investigators would be able to use these differences as a&#xD;
      biomarker which would enable us to develop a quick screening test for bacterial samples that&#xD;
      may reveal whether a person has PD or not.&#xD;
&#xD;
      By doing this study the investigators will learn whether bacteria play a role in the&#xD;
      development of PD and whether the investigators can use them as a biomarker or therapeutic&#xD;
      target. So hopefully the investigators will be able in the future to better understand what&#xD;
      causes PD, how the investigators can diagnose it as early as possible and how to cure&#xD;
      patients from PD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson patients</arm_group_label>
    <description>Parkinson patients, symptom onset &gt; 50 years of age, non-smoker, no relevant gastrointestinal or ENT diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <description>No parkinsonism, age and gender matched to PD subjects, non-smoker, no relevant gastrointestinal or ENT diseases</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal and oral bacterial swabs and stool samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital patients in- and outpatient From the community&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over 50 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  relevant gastrointestinal or ENT disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip Scheperjans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jorvi Hospital</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Biotechnology, Helsinki University</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyvinkää Hospital</name>
      <address>
        <city>Hyvinkää</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peijas Hospital</name>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Filip Scheperjans</investigator_full_name>
    <investigator_title>Neurologist</investigator_title>
  </responsible_party>
  <keyword>Metagenomic analysis</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

